These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 8733411)
21. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251 [TBL] [Abstract][Full Text] [Related]
23. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn P Trans R Soc Trop Med Hyg; 1995; 89(1):78-82. PubMed ID: 7747316 [TBL] [Abstract][Full Text] [Related]
24. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100 [TBL] [Abstract][Full Text] [Related]
25. Tuberculosis and human immunodeficiency virus infection in developing countries. Harries AD Lancet; 1990 Feb; 335(8686):387-90. PubMed ID: 1968123 [TBL] [Abstract][Full Text] [Related]
26. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Nunn P; Kibuga D; Gathua S; Brindle R; Imalingat A; Wasunna K; Lucas S; Gilks C; Omwega M; Were J Lancet; 1991 Mar; 337(8742):627-30. PubMed ID: 1705647 [TBL] [Abstract][Full Text] [Related]
27. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. Foster S; Godfrey-Faussett P; Porter J AIDS; 1997 Jun; 11(7):919-25. PubMed ID: 9189218 [TBL] [Abstract][Full Text] [Related]
29. Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. Harries AD; Nyong'Onya Mbewe L; Salaniponi FM; Nyangulu DS; Veen J; Ringdal T; Nunn P Lancet; 1996 Mar; 347(9004):807-9. PubMed ID: 8622340 [TBL] [Abstract][Full Text] [Related]
30. The proportion of tuberculosis cases in Tanzania attributable to human immunodeficiency virus. van Cleeff MR; Chum HJ Int J Epidemiol; 1995 Jun; 24(3):637-42. PubMed ID: 7672908 [TBL] [Abstract][Full Text] [Related]
31. Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon. Kuaban C; Bercion R; Koula-Shiro S Cent Afr J Med; 1998 Feb; 44(2):34-7. PubMed ID: 9675969 [TBL] [Abstract][Full Text] [Related]
32. Rebuttal: time to call a halt to emotions in the assessment of thioacetazone. Rieder HL; Enarson DA Tuber Lung Dis; 1996 Apr; 77(2):109-11. PubMed ID: 8762843 [No Abstract] [Full Text] [Related]
33. Use of thiacetazone. Wilkinson D; Moore D Lancet; 1995 Jan; 345(8941):63. PubMed ID: 7528313 [No Abstract] [Full Text] [Related]
34. Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. Gilks CF; Godfrey-Faussett P; Batchelor BI; Ojoo JC; Ojoo SJ; Brindle RJ; Paul J; Kimari J; Bruce MC; Bwayo J; Plummer FA; Warrell DA AIDS; 1997 Jun; 11(7):911-8. PubMed ID: 9189217 [TBL] [Abstract][Full Text] [Related]
35. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. Floyd K; Wilkinson D; Gilks C BMJ; 1997 Nov; 315(7120):1407-11. PubMed ID: 9418087 [TBL] [Abstract][Full Text] [Related]
36. Thiacetazone skin reaction in Papua New Guinea. Naraqi S; Temu P Med J Aust; 1980 May; 1(10):480-1. PubMed ID: 6157976 [TBL] [Abstract][Full Text] [Related]
37. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
38. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. Githui W; Nunn P; Juma E; Karimi F; Brindle R; Kamunyi R; Gathua S; Gicheha C; Morris J; Omwega M Tuber Lung Dis; 1992 Aug; 73(4):203-9. PubMed ID: 1477386 [TBL] [Abstract][Full Text] [Related]
39. Some effects of the rising case load of adult HIV-related disease on a hospital in Nairobi. Gilks CF; Floyd K; Otieno LS; Adam AM; Bhatt SM; Warrell DA J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):234-40. PubMed ID: 9665500 [TBL] [Abstract][Full Text] [Related]
40. The point of view of a high prevalence country: Malawi. Nyangulu DS Bull Int Union Tuberc Lung Dis; 1991 Dec; 66(4):173-4. PubMed ID: 1687509 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]